If joining a truly innovative medtech company may be part of your end-of-year resolutions, we have good news for you: Xeltis is hiring! We are expanding our device development and clinical trial programs and scaling up our R&D, Clinical [...]
The Xeltis materials have been showing outstanding restorative outcomes in preclinical trials presented by Dr Madeline Cramer, University of Pittsburgh, at the Polymers in Medicine and Biology Workshop, Napa (CA - USA) on Wednesday 30 November. The favourable outcomes included [...]
Professor Frans Moll, University Medical Center Utrecht, will update an audience of international vascular surgeons at the VEITH Symposium in New York City this Saturday. In a session on new technologies for vascular access creation, Professor Moll will provide [...]
Dr An de Vriese, who is playing a leading role in the ongoing European pivotal trial investigating the aXess vascular graft, discussed the study and the significant potential held by Xeltis’ technology in dialysis access care in Renal Interventions. [...]
Xeltis has started the pivotal trial for the first-ever restorative synthetic hemodialysis access grafts, aXess. The first two patients have been successfully implanted, as part of the AXESS European pivotal trial at AZ Sint-Jan Brugge-Oostende AV in Bruges, Belgium [...]
Preclinical data on Xeltis restorative Coronary Artery Bypass Graft (CABG) device, XABG, show unprecedented one-year patency for a CABG device, potentially superior to saphenous veins. It is the most prolonged patency ever demonstrated for a small-diameter (4mm diameter; 15cm [...]
Xeltis is looking for a Senior R&D Engineer (Chemical Process and Polymers) to contribute to the design and development of next generation bioresorbable vascular grafts which utilize endogenous tissue restoration (ETR). Xeltis is a clinical stage medical device company [...]
Xeltis’ restorative pulmonary heart valve is featuring at the prestigious Pulmonary Heart Valve Global Multidisciplinary Workshop organized by the US Food and Drug Administration (FDA) in conjunction with the Heart Valve Collaboratory on October 14 and 15, 2022. Doctor David [...]
Enrolment in the AXESS first-in-human (FIH) trial of Xeltis’ restorative hemodialysis vascular access graft, aXess, has been completed, with 20 patients successfully implanted. Very promising preliminary efficacy and safety results from one of the participating centers will be presented [...]
On World Heart Day, we renew Xeltis’ pledge to make the difference for patients with heart disease. Cardiovascular disease can be controlled, treated and improved but it is with a patient day in, day out. Likewise, we work day in, [...]
